Aside from Vitamin B12, it contains choline, methionine, and inositol
The specific compounds now under PCAC review carry decades of independent research behind them: GHK-Cu was first characterised in a 1980 Nature paper by Loren Pickart as a copper-binding plasma tripeptide
GHK-Cu is often prescribed for its potential benefits in promoting tissue repair, reducing inflammation, and supporting neuroregeneration
It catalyzes the removal of H + ions from glucose-6-phosphate to produce 6-phosphogluconate and requires a cofactor, NADP
Self-reported dose per injection Median bucket: 0.20.4 mg Most common: 0.20.4 mg Reports span 0.1 to 5 mg (open-ended top bucket) Anonymized self-reports from PeptIQ users not prescribing guidance
User protocols typically employ 0.25 to 0.5 mg daily via subcutaneous injection near the injured tendon for four to eight weeks